Ge Healthcare Technologies Inc Stock Price, News & Analysis

GE HealthCare and MediView XR announced the world's first installation and clinical use of the OmnifyXR Interventional Suite at North Star Vascular and Interventional in Minnesota. The augmented reality-based system, which features a heads-up holographic display, aims to revolutionize interventional radiology by providing advanced imaging, 3D anatomy visualization, and remote collaboration capabilities. The system supports workflow efficiency, improved visualization, and collaborative care. The first clinical procedures using OmnifyXR were the embolization of a genicular artery and a prostate artery. OmnifyXR is currently available in the U.S. and will expand globally.

GE HealthCare (Nasdaq: GEHC) has announced key leadership changes and the realignment of its Imaging and Ultrasound segments. Roland Rott will become the president and CEO of Imaging, while Phil Rackliffe will lead Ultrasound and Image Guided Therapies (IGT). This restructuring, effective July 1, 2024, aims to enhance patient care and business performance. IGT, a $1.6 billion subsegment of Imaging, will merge with Ultrasound in Q3 2024, creating a $5.0 billion global business. Imaging, GE HealthCare’s largest segment, will focus on surgical and interventional procedures, generating over $8.9 billion in annual revenue. The new leadership is expected to drive innovation and growth, leveraging their extensive experience in healthcare and technology.

GE HealthCare has introduced new technologies at the SNMMI 2024 meeting to enhance precision and personalized medicine globally.

The additions include MINItrace Magni, a compact cyclotron for in-house PET tracer production; Omni Legend 21 cm, a versatile PET/CT scanner; and Clarify DL, a deep learning reconstruction tech for clear imaging. These innovations aim to address global healthcare disparities, especially in underserved regions where access to diagnostic imaging is

The company also highlighted its recently acquired MIM Software solutions, which support precise, connected, and efficient care across disease states. A pharmaco-economic study suggests that using a breast oncology PET tracer in diagnostics may save the US healthcare system $142M over five years.

GE HealthCare's study demonstrates that adding a PET/CT scan with the [18F]FES breast oncology tracer to the standard diagnostic process for metastatic or recurrent breast cancer patients could save the US healthcare system $142M over five years. The tracer improves diagnostic accuracy for estrogen receptor (ER) status, especially when biopsy samples are unobtainable or risky, reducing the need for repeated biopsies and ineffective treatments. Published in PLOS ONE, the study shows up to an 8% increase in accurate ER status results. Cerianna, the only FDA-approved [18F]FES PET imaging agent, is now included in the NCCN Clinical Practice Guidelines for certain breast cancer cases, further supporting its clinical and economic benefits.

GE HealthCare (Nasdaq: GEHC) and Tampa General Hospital (TGH) are expanding their long-term partnership to deploy GE HealthCare’s Imaging and Ultrasound technology solutions across TGH Imaging’s outpatient facilities in Florida. This collaboration aims to provide more precise and timely diagnoses, improving patient outcomes and treatment plans. TGH Imaging operates 21 locations with over 65 board-certified radiologists. Previous successful implementations include a command center with GE HealthCare’s Command Center Software and a capital refresh plan for imaging technologies. TGH Imaging was also the first in Florida to install GE HealthCare’s Omni Legend digital PET/CT system in March 2023.

GE HealthCare has secured the top spot in the FDA's list of AI-enabled medical devices for the third consecutive year, with 72 devices authorized in the U.S. to date.

This achievement is part of the company's strategy to invest in AI and machine learning to enhance precision care, a holistic approach integrating multiple technologies for optimal patient outcomes.

Key authorized devices include Precision DL for enhanced lesion detectability, Contour ProtégéAI+ for radiation oncology, and Caption Interpretation Automated Ejection Fraction Software for cardiac evaluations. This recognition underlines GE HealthCare's commitment to leveraging advanced technologies to address industry challenges and improve healthcare delivery.

GE HealthCare (Nasdaq: GEHC) and Medis Medical Imaging have announced a collaboration to advance precision care in coronary artery disease (CAD) treatment. They aim to integrate Medis QFR, a non-invasive coronary physiology assessment tool, into GE HealthCare's Allia Platform. This collaboration seeks to simplify the cath lab environment and provide clinicians with better diagnostic tools. Recent studies support the benefits of QFR-guided lesion selection for PCI, showing improved clinical outcomes. Medis’ QFR technology, which has been developed over a decade, will be more accessible to clinicians, enhancing GE HealthCare’s cardiology solutions portfolio.

GE HealthCare (GEHC), a Nasdaq-listed precision care innovation leader, will hold an investor day in New York City on November 21, 2024. The event will feature presentations on growth strategies, technology portfolio, and business vision via a live webcast.

GE HealthCare introduced SIGNA MAGNUS, a head-only MR scanner, to advance neuroscience research by overcoming limitations of whole-body MR systems. The system aims to enhance MR research in neurology, oncology, and psychiatry, offering superior gradient performance and deep-learning algorithms to explore brain microstructure and function. This innovation is set to revolutionize medical research and patient care, empowering researchers to uncover new parameters and biomarkers. SIGNA MAGNUS has the potential to impact patient outcomes and enhance our understanding of the human brain.